RESUMEN
Prostamol Uno (PU) efficacy and safety were studied in a multicenter, open-population, randomized and comparative trial. PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls. The trial evaluated PU action on the symptoms progression and quality of life with application of questionnaires IPSS and QoL (BS). It was found that PU treatment relieved PA symptoms by IPSS, while these symptoms progressed in the controls. QoL improved in the study group and deteriorated in the control one. Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased, size of the prostate diminished and increased, respectively. Changes in the PSA were not seen and were insignificant, respectively. The results of the study say that prostamol Uno in a dose 320 mg/day can prevent PA progression without side effects.
Asunto(s)
Extractos Vegetales/uso terapéutico , Hiperplasia Prostática/tratamiento farmacológico , Progresión de la Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Tamaño de los Órganos , Extractos Vegetales/administración & dosificación , Extractos Vegetales/efectos adversos , Próstata/diagnóstico por imagen , Próstata/efectos de los fármacos , Antígeno Prostático Específico/sangre , Hiperplasia Prostática/complicaciones , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/fisiopatología , Calidad de Vida , Riesgo , Resultado del Tratamiento , Ultrasonografía , Vejiga Urinaria/diagnóstico por imagen , Vejiga Urinaria/fisiopatología , Retención Urinaria/etiología , Retención Urinaria/fisiopatología , Retención Urinaria/prevención & control , Urodinámica/efectos de los fármacosRESUMEN
The article presents 2-year pilot results of a multicenter, randomized, controlled trial of prostamol-UNO effects on symptoms progression, quality of life, tolerance and safety in patients with early prostatic adenoma. The drug was used in a single dose 320 mg/day for 36 months. Prostamol-UNO efficacy in arrest of the symptoms progression and quality of life was assessed with the use of IPSS and QoL (BS) questionnaires. Measurements were also made of changes in Qmax, urine volume, residual urine, size of the prostate.
Asunto(s)
Hiperplasia Prostática/tratamiento farmacológico , Progresión de la Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Extractos Vegetales , Hiperplasia Prostática/patología , Hiperplasia Prostática/orina , Calidad de Vida , Factores de Riesgo , Factores de TiempoRESUMEN
Twenty patients with psychogenic erectile dysfunction received the drug enerion (Hungary). After a 30-day course of enerion erectile function improved in 16 of the above patients. A mean value of the international index of erectile function (IIEF) increased in them from 17.5 to 24.8 points. Improvement of cavernous arterial blood flow after the treatment was seen in 3 of 6 patients with arterial disorders. As shown by electromyographic examinations, cavernous electric activity normalized in 8 patients. Thus, psychogenic erectile dysfunction can be effectively treated with enerion.